**Multicenter Study of Cronobacter sakazakii Infections in Humans, Europe, 2017**

Sarah Lepuschitz, Werner Ruppitsch, Shiva Pekard-Amenitsch, Stephen J. Forsythe, Martin Cormican, Robert L. Mach, Denis Piérard, Franz Allerberger, the EUCRONI Study Group

Cronobacter sakazakii has been documented as a cause of life-threatening infections, predominantly in neonates. We conducted a multicenter study to assess the occurrence of C. sakazakii across Europe and the extent of clonality for outbreak detection. National coordinators representing 24 countries in Europe were requested to submit all human C. sakazakii isolates collected during 2017 to a study center in Austria. Testing at the center included species identification by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, subtyping by whole-genome sequencing (WGS), and determination of antimicrobial resistance. Eleven countries sent 77 isolates, including 36 isolates from 2017 and 41 historical isolates. Fifty-nine isolates were confirmed as C. sakazakii by WGS, highlighting the challenge of correctly identifying Cronobacter spp. WGS-based typing revealed high strain diversity, indicating absence of multinational outbreaks in 2017, but identified 4 previously unpublished historical outbreaks. WGS is the recommended method for accurate identification, typing, and detection of this pathogen.

Cronobacter sakazakii is a motile, gram-negative, rod-shaped opportunist pathogen of the family Enterobacteriaceae (1). In 2007, organisms previously classified as Enterobacter sakazakii were reassigned to the new genus Cronobacter, which now consists of 7 species: C. sakazakii, C. condimenti, C. dublinensis, C. malonicatus, C. muytjensii, C. turicensis, and C. universalis (2,3). C. sakazakii has been isolated from various environments (e.g., domestic environments and manufacturing plants), clinical sources (e.g., cerebrospinal fluid, blood, and sputum), food (e.g., cheese, meat, and vegetables), and animals (e.g., rats and flies) (4,5).

Most reported cases of illness caused by C. sakazakii are in infants <2 months old (6,7). Premature infants and infants with underlying medical conditions are at the greatest risk for illness. Numerous outbreaks caused by C. sakazakii have been traced to contaminated powdered infant formula (8). Powdered infant formula is not a sterile product, and the ability of C. sakazakii to tolerate dry conditions enables it to survive for long periods in the final powdered product (9).

The screening of food (particularly powdered formula) was proposed to reduce the risk to neonatal and infant health (10,11). The most common syndromes of foodborne infection in infants include necrotizing enterocolitis (NEC), bacteremia, and meningitis (12,13). Examples of outbreaks of illness in hospital neonatal units caused by C. sakazakii associated with powdered infant formula have been compiled by Iversen and Forsythe (6) and by Lund (8).

A few cases of illness (usually nongastrointestinal) in adults caused by C. sakazakii have been reported. In most of these cases the adults had underlying diseases, and no evidence of foodborne transmission was reported (14,15).

We performed a multicenter study of C. sakazakii infections in humans (EUCRONI) to determine the occurrence of C. sakazakii in clinical microbiology laboratories across Europe. We also assessed the extent of clonality for human C. sakazakii isolates.

**Material and Methods**

**Study Design**

EUCRONI consisted of national coordinators (EUCRONI study group members) from 24 countries in Europe. Coordinators had to actively approach all medical microbiology laboratories to collect human C. sakazakii isolates (1 per patient) in their respective countries during 2017. Human historical isolates (with isolation dates before 2017) were also accepted. The 24 participating countries were arbitrarily chosen to reflect a wide geographic and

---

1Members of the EUCRONI study group are listed at the end of this article.
socioeconomic range (Figure 1). Isolates were transferred to the study center (Austrian Agency for Health and Food Safety, Vienna, Austria) for whole-genome sequencing (WGS), matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) analysis, and antimicrobial drug susceptibility testing. We submitted data capture forms to national coordinators to collect the following demographic data: patient age and sex, patient status (colonized or infected), specimen source, type of healthcare facility requesting the microbiologic culture, and date of specimen collection.

**Species Identification and DNA Extraction**

We cultured isolates on Columbia blood agar plates (bio-Mérieux, http://www.biomerieux.com/) overnight at 37°C. We performed species identification by using MALDI-TOF Biotyper (Bruker, https://www.bruker.com) and MBT Compass IVD 4.1.60 (Bruker) according to the manufacturer’s instructions. We conducted isolation, quantification, and WGS of genomic DNA according to methods described by Lepuschitz et al. (16). We used Sequencing Coverage Calculator (http://www.illumina.com) for calculation of a desired mean coverage of ≥80-fold.

**WGS Data Analysis**

We de novo assembled raw reads by using SPAdes version 3.9.0 (17) and processed them in SeqSphere+ (Ridom GmbH, https://www.ridom.de) for bacterial typing. We deposited the genome sequences in the PubMLST *Cronobacter* database (https://pubmlst.org/Cronobacter) under accession nos. 2403 and 2495–2552. To determine the core genome multilocus sequence type (cgMLST) gene set, we performed a genome-wide gene-by-gene comparison by using the MLST+ target definer function of SeqSphere+.

![Figure 1. Countries participating in a multicenter study of *Cronobacter sakazakii* infections in humans, Europe, 2017. Dark green indicates the 8 countries that sent *C. sakazakii* isolates to the study center in Austria; light green indicates the 3 countries where historical outbreaks were detected; and red indicates the 13 countries that participated but did not provide isolates. AT, Austria; BE, Belgium; BG, Bulgaria; CH, Switzerland; CY, Cyprus; CZ, Czech Republic; DE, Germany; DK, Denmark; ES, Spain; FR, France; GR, Greece; HR, Croatia; IE, Ireland; IT, Italy; LV, Latvia; NL, Netherlands; NO, Norway; PL, Poland; PT, Portugal; RO, Romania; RS, Serbia; SE, Sweden; SI, Slovenia; UK, United Kingdom.](http://www.cdc.gov/eid)
as described previously (18) with default parameters and the complete genome of C. sakazakii strain ATCC BAA-894 (19) as reference genome, all complete C. sakazakii genomes available at GenBank, 8 isolates retrieved from whole-genome shotgun sequencing projects, and 4 C. sakazakii isolates sequenced at the Austria study center as query genomes. We extracted sequences of the 7 genes comprising the allelic profile of the classical MLST scheme and queried them against the C. sakazakii MLST database (1), assigning classical sequence types (STs) in silico. We obtained additional species confirmation by using JSPECIESWS (20) and ribosomal MLST (21). We included 23 C. sakazakii historical isolates from 4 different outbreaks (F. Allerberger, 2016; F. Barbut, 2010–2016; G. Feierl, 2009; D. Piérard, 1997–1998, all unpub. data; Appendix Table 1, https://wwwnc.cdc.gov/EID/article/25/3/18-1652-App1.xlsx) and 3 reference strains, ATCC BAA-894 (19), ATCC29544 (PRJNA224116), and NCTC 8155 (PRJNA224116), to determine the level of microevolution.

Antimicrobial Resistance Testing
We performed in vitro susceptibility testing with the VITEK 2 Compact System (bioMérieux) and interpreted the VITEK 2 AST196 card according to European Committee on Antimicrobial Susceptibility Testing criteria for Enterobacteriaceae (Clinical Breakpoint Tables version 8.0, http://www.eucast.org/ast_of_bacteria/previous_versions_of_documents). For detection of antibiotic resistance genes, we used the Comprehensive Antibiotic Resistance Database (22) with default settings “perfect” and “strict” for sequence analysis. We tested isolates in SeqSphere+ for Cronobacter-specific variant ampC (e.g., CSA-1, CSA-2, CMA-1, and CMA-2) (23).

Results

Strain Collection and Primary Species Identification
During the study period, 11 of 24 national coordinators (Figure 1) provided 77 presumptive C. sakazakii isolates previously identified by conventional biochemical testing, local MALDI-TOF MS analysis (Bruker Biotyper and VITEK MS), locally performed Cronobacter genus- and species-specific PCRs, or 16S rRNA gene sequence analysis. These 77 isolates consisted of 36 human isolates from 2017 and 41 historical human isolates obtained during 1964–2016. The participating laboratories, using local conventional phenotypical methods or local MALDI-TOF MS analysis, incorrectly identified 18 (23.4%) of 77 human isolates as C. sakazakii.

MALDI-TOF MS analysis in the study center identified 69 of 77 isolates as C. sakazakii; 1 isolate from 2017 yielded low-confidence identification (log[score] value 1.70–1.99). We assigned 2 clinical isolates from 2017 and 1 historical clinical isolate from 2005 to other species (Table 1). The WGS-based species identification using JSPECIESWS and rMLST confirmed MALDI-TOF MS identification results in all but 10 of the 69 isolates. WGS indicated that 5 isolates were C. malonaticus, 2 were C. turicensis, 1 was C. dublinensis, 1 was C. universalis, and 1 was Siccibacter turicensis (Table 1; Appendix Table 1).

Human C. sakazakii Isolates Collected in 2017
In total, 21 C. sakazakii isolates from 21 patients were collected in 2017 in 9 participating countries in Europe. Case-fatality ratio (within 30 days after specimen collection) was 2 of 21 case-patients (Table 2).

Molecular Typing of Bacterial Isolates
The defined cgMLST gene set consisted of a total of 2,831 core and 1,017 accessory targets. Of 77 sequenced isolates, 59 isolates were confirmed as C. sakazakii; 1 isolate from 2017 had on average 99.4% of good core genome targets (97.7% to 99.9%) (18) and revealed in total 17 different sequence types (STs) (Table 3).

Core genome comparison of 59 C. sakazakii isolates and the 3 reference strains revealed an average allelic difference of 2,402 and a maximum allelic difference of 2,724 (Figure 2). Isolates clustered in the minimum-
spanning tree to their respective MLST. Eight isolates belonging to ST1 included 2 stool isolates from neonates with a common epidemiologic link in Austria in 2009; these 8 isolates showed 1 allelic difference and were most closely related (203 alleles difference) to a historical strain from Denmark isolated in 2003. That outbreak affected 2 neonates with necrotizing enterocolitis (both male, age 10 days and 12 days) hospitalized in the same neonatal intensive care unit.

Twelve isolates belonged to ST4, of which 3 were confirmed isolates from infants. Two infant isolates belonged to an outbreak cluster with a common epidemiologic link in Austria during 1997–1998; all 10 isolates assigned to ST155 belonged to a historical outbreak cluster from France collected during 2010–2011. These 6 isolates shared the identical core genome genes, and 1 yielded 1 allelic difference.

All 10 isolates assigned to ST155 belonged to a historical outbreak among infants in Belgium during 1997–1998; the isolates originated from blood cultures (n = 2), stool specimens (n = 2), rectal swab specimens (n = 4), and respiratory tract specimens (n = 2). The first positive sample was collected in November 1997; the remaining 9 specimens were obtained during August–September 1998. Eight

<table>
<thead>
<tr>
<th>Sample ID</th>
<th>Country of origin</th>
<th>Patient age, y/sex</th>
<th>Specimen source</th>
<th>Death within 30 d</th>
<th>MLST</th>
</tr>
</thead>
<tbody>
<tr>
<td>802520</td>
<td>Austria</td>
<td>73/F</td>
<td>Stool</td>
<td>No</td>
<td>630</td>
</tr>
<tr>
<td>7750-17</td>
<td>Austria</td>
<td>&lt;1/M</td>
<td>Blood</td>
<td>Yes</td>
<td>4</td>
</tr>
<tr>
<td>16862-17</td>
<td>Austria</td>
<td>77/F</td>
<td>Blood</td>
<td>No</td>
<td>37</td>
</tr>
<tr>
<td>808921</td>
<td>Austria</td>
<td>69/F</td>
<td>Blood</td>
<td>No</td>
<td>21</td>
</tr>
<tr>
<td>56487-17</td>
<td>Austria</td>
<td>78/M</td>
<td>Urine</td>
<td>No</td>
<td>17</td>
</tr>
<tr>
<td>101807-17</td>
<td>Austria</td>
<td>77/M</td>
<td>Blood</td>
<td>No</td>
<td>1</td>
</tr>
<tr>
<td>9929-17</td>
<td>Austria</td>
<td>5/M</td>
<td>Stool</td>
<td>No</td>
<td>17</td>
</tr>
<tr>
<td>EUCRONI016</td>
<td>Belgium</td>
<td>61/M</td>
<td>Urine</td>
<td>No</td>
<td>13</td>
</tr>
<tr>
<td>EUCRONI012</td>
<td>Belgium</td>
<td>78/M</td>
<td>Wound</td>
<td>No</td>
<td>31</td>
</tr>
<tr>
<td>1481-17</td>
<td>Czech Republic</td>
<td>80/F</td>
<td>Rectal swab</td>
<td>No</td>
<td>8</td>
</tr>
<tr>
<td>436-17</td>
<td>Czech Republic</td>
<td>31/M</td>
<td>Rectal swab</td>
<td>No</td>
<td>4</td>
</tr>
<tr>
<td>10965-17</td>
<td>Czech Republic</td>
<td>74/M</td>
<td>Rectal swab</td>
<td>No</td>
<td>4</td>
</tr>
<tr>
<td>D97986</td>
<td>Denmark</td>
<td>85/F</td>
<td>Sputum</td>
<td>No</td>
<td>1</td>
</tr>
<tr>
<td>17007483</td>
<td>Denmark</td>
<td>69/M</td>
<td>Urine</td>
<td>No</td>
<td>58</td>
</tr>
<tr>
<td>423410</td>
<td>Ireland</td>
<td>65/M</td>
<td>Blood</td>
<td>No</td>
<td>12</td>
</tr>
<tr>
<td>170215-0130</td>
<td>Norway</td>
<td>87/M</td>
<td>Blood</td>
<td>Yes</td>
<td>17</td>
</tr>
<tr>
<td>M732000</td>
<td>Portugal</td>
<td>60/M</td>
<td>Urine</td>
<td>No</td>
<td>40</td>
</tr>
<tr>
<td>80357408-17</td>
<td>Scotland</td>
<td>73/F</td>
<td>Stool</td>
<td>No</td>
<td>33</td>
</tr>
<tr>
<td>80363028-17</td>
<td>Scotland</td>
<td>71/M</td>
<td>Urine</td>
<td>No</td>
<td>4</td>
</tr>
<tr>
<td>07_2005</td>
<td>Slovenia</td>
<td>54/M</td>
<td>Tracheal aspirate</td>
<td>No</td>
<td>184</td>
</tr>
<tr>
<td>2017C1</td>
<td>Switzerland</td>
<td>55/F</td>
<td>Cervix uteri</td>
<td>No</td>
<td>40</td>
</tr>
</tbody>
</table>

*MLST, multilocus sequence type.
Cronobacter sakazakii infections in humans, Europe

In total, 27 of 38 historical isolates were most closely related (≤1 allelic difference) to other historical isolates; 11 were singletons. All 21 isolates collected in 2017 were singletons, and no close relatedness was evident (>100 allelic differences) between historical isolates and isolates from 2017.

In vitro and in silico antimicrobial resistance analysis

In vitro susceptibility testing of 21 human C. sakazakii isolates from 2017 revealed 20 C. sakazakii isolates that were susceptible to all 14 tested antibiotics (Appendix Table 2). One isolate was resistant to ampicillin, cefotaxime, gentamicin (intermediate), moxifloxacin, and trimethoprim/sulfamethoxazole.

Of 21 C. sakazakii isolates, 12 isolates carried the efflux genes emrB, mshA, pta, regulatory systems modulating antibiotic efflux CRP, marA, emrR, marR, H-NS, antibiotic target protection gene msrB, and the determinant of fosfomycin resistance glpT. Seven isolates had in addition the antibiotic protection gene vgaC. One isolate had also the efflux gene norB, the antibiotic inactivation gene fosX, and the antibiotic target alteration gene mprF. One isolate had the additional antibiotic inactivation genes aac(6')-Ib-cr, aadA16, aadA2, ant(2’)-Ia, arr-3, catB3, CTX-M-9, OXA-1, the antibiotic target protection gene qnrA1, and the antibiotic target replacement gene sul1.

The presence of variant ampC was confirmed for all 21 isolates. Seventeen isolates harbored CSA-2, and 4 isolates harbored CSA-1 (Appendix Table 2).

Discussion

The aim of our 2017 C. sakazakii study was to assess the occurrence of this opportunistic pathogen in countries of Europe, characterize the isolates, and recognize possible multinational outbreaks. Our finding that only 59 of 77 presumptive C. sakazakii isolates had the species-identification
C. sakazakii confirmed at the central study center shows that correct identification of Cronobacter spp. is still a challenge for many routine laboratories.

The prevalence of reported C. sakazakii cases was low, with only 11 (45.8%) of 24 participating countries submitting C. sakazakii isolates. Clinical isolates from 2017 showed high genetic diversity, indicating that neither multinational nor national outbreaks occurred in 2017 in the 24 countries studied. However, characterization of the historical isolates obtained during this study confirmed occurrence of 4 previously unpublished historical outbreaks: 2 outbreaks from 2009 and 2016 in Austria, 1 from Belgium during 1997–1998, and 1 from France during 2010–2016. Hospitals affected by nosocomial C. sakazakii outbreaks might still be reluctant to publish possibly food-related outbreaks or nosocomial infections, especially in the case of affected infants and particularly in the case of related fatalities.

Strain typing using classical MLST identified a total of 17 STs among 59 sequenced C. sakazakii isolates. Our addition of a new ad hoc cgMLST scheme consisting of 2,831 core target genes provides more discriminative power for outbreak investigation and source tracking than the standard 7-loci MLST scheme.

The dominant STs found among our clinical C. sakazakii isolates from 2017 were ST4, ST17, ST1, and ST40, a distribution consistent with results from other studies (1). The medical literature often links C. sakazakii ST4 with powdered infant formula–associated outbreaks in infants (3). In our study, the sole strain (7750-17) affecting an infant (a 3-month-old baby boy who died) was ST4, isolated from a blood culture.

Antibiotic treatment is essential in the care of a patient with a confirmed Cronobacter infection. The traditional antibiotic regimen for Cronobacter spp. was ampicillin in combination with either gentamicin or chloramphenicol. In view of claimed resistance to ampicillin and most first- and second-generation cephalosporins, it has been suggested that carbapenems or third-generation cephalosporins be used with an aminoglycoside or trimethoprim/sulfamethoxazole (24). In our study, antimicrobial resistance testing showed susceptibility to all tested antibiotics for 20 of 21 human isolates from 2017. In comparison to other members of the family Enterobacteriaceae, Cronobacter strains seem to be more susceptible against so-called “key access antibiotics” of the World Health Organization’s Model List of Essential Medicines (25), such as ampicillin, aminoglycosides, chloramphenicol, and third-generation cephalosporins (the last is included in the List of Essential Medicines only for specific, limited indications) (26). For all isolates, we confirmed the presence of 1 of 4 tested ampC β-lactamase variants, which confer phenotypic resistance exclusively to first-generation cephalosporins (e.g., cephalothin) but not to ampicillin (23). A few studies have reported Cronobacter isolates conferring multidrug resistance (26), a phenomenon observed in our study only for 1 strain from Slovenia.

Correct species identification within the Cronobacter group was a major challenge for 7 of 11 participating laboratories. This identification problem is consistent with numerous misidentifications reported in the literature (27,28). The discrepancies in correct Cronobacter spp. identification on a genus and species level between the study center in Austria and the primary testing laboratories using MALDI-TOF MS is probably attributable to outdated databases used by primary testing laboratories. Nevertheless, our study showed that the overall MALDI-TOF MS performance for Cronobacter spp. identification on the species level is insufficient and misleading. The databases contained data for C. sakazakii only, and therefore all 7 species of the genus Cronobacter were identified as C. sakazakii. In addition, although a database comment indicated that Cronobacter could only be identified on the genus level, the MALDI-TOF MS result simulated the highest identification score for C. sakazakii. This shortfall should be corrected by an update of the MALDI-TOF MS databases to enable accurate Cronobacter identification at the species level. In comparison, WGS-based species identification represents a major improvement to conventional identification methods and MALDI-TOF MS (29). Therefore, we recommend the use of WGS-based identification tools and databases for identification of species within the Cronobacter group.

Adults were the main affected age group in our study. All but 2 of the isolates from 2017 originated from adults. This finding confirms the results from previous recent studies (14,30) and contradicts statements in numerous medical textbooks, postulating that infants are more often affected than adults (8,31–33).

Our study has some limitations. Lack of information (e.g., detailed epidemiologic and clinical patient data) and misidentification on genus and species levels, might have played a role in underestimating the real prevalence rate; 13 of the 24 participating countries did not find or did not submit C. sakazakii isolates.

In conclusion, this C. sakazakii study in Europe revealed a high strain diversity, which points to highly diverse infection sources and an absence of national or multinational outbreaks in 2017. Correct identification of C. sakazakii still poses a diagnostic challenge to many laboratories, and the use of such imperfect detection systems might explain the low prevalence of reported clinical C. sakazakii isolates found in this study. WGS data must be used for accurate species identification and high-resolution strain typing. We recommend the inclusion of C. sakazakii as a notifiable organism by public health authorities.
Members of the EUCRONI study group: F. Allerberger, Austrian Agency for Health and Food Safety, Vienna, Austria; A. Tamberi Andrasevic, University Hospital for Infectious Diseases, Zagreb, Croatia; A. Balode, Pauls Stradiņš Clinical University Hospital, Riga, Latvia; F. Barbut, Hôpital Saint-Antoine, Paris, France; Irina Codita, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; M. Cormican, School of Medicine National University of Ireland Galway, Galway, Ireland; C. Ferguson, Victoria Hospital, Kirkcaldy, Scotland, United Kingdom; P. Heczko, Jagiellonian University Medical College, Kraków, Poland; O. Holy, Department of Preventive Medicine, Palacky University Olomouc, Czech Republic; T. Kantardjiev, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria; E.J. Kuijper, Leiden University Medical Center, Leiden, the Netherlands; T.M. Leegaard, Akershus University Hospital, Lorenskog, Norway; L.M.V. Peixe, University of Porto, Porto, Portugal; D. Piéard, Department of Laboratory Medicine, Universitair Ziekenhuis Brussel, Belgium; H. Rautelin, Uppsala University, Uppsala, Sweden; M. Rupnik, Nacionalni Laboratorij za Zdravje, Okolje in Hrano, Maribor, Slovenia; K. Schönnung, Hvidovre Hospital, Hvidovre, Denmark; R. Stephan, Institute for Food Safety and Hygiene, University of Zurich, Zurich, Switzerland; A. Tonilo, Universitàt degli Studi dell’Insubria, Varese, Italy; T. Tošić, Clinical Center of Serbia, Belgrade, Serbia; S. Valdezate, Instituto de Salud Carlos III, Madrid, Spain; L. von Müller, Christophorus-Kliniken GmbH, Coesfeld, Germany; L. Zerva, Attikon-Hospital, Athens, Greece; and B. Zinieri-Panayide, General Hospital, Paphos, Cyprus.

Acknowledgments


Address for correspondence: Sarah Lepuschitz, Austrian Agency for Health and Food Safety, Institute for Medical Microbiology and Hygiene, Waehringerstraße 25a, 1090 Vienna, Austria; email: sarah.lepuschitz@ages.at